In a small study that included 12 legally blind participants, use of a portable artificial vision device improved the patient’s ability to perform tasks simulating those of daily living, such as…
RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences
ANN ARBOR, Mich.–(BUSINESS WIRE)–CEO Sean Ainsworth will highlight RetroSense’s contributions to gene therapy research during panel presentations at the NY BIO 2016 Annual Meeting and the Piper Jaffray GenomeRx Symposium.
Uncategorized
ARMOR study shows antibiotic resistance levels remain high
SEATTLE – Preliminary 2015 data from the Antibiotic Resistance Monitoring in Ocular Microorganism study show that high levels of antibiotic resistance continue among Staphylococcus, especially the methicillin-resistant strains, according to a poster presented here at the Association of Research in Vision and Ophthalmology meeting. Christine Sanfilippo, PhD, manager of pharmaceutical medical affairs, Bausch + Lomb, told Primary Care Optometry News, “There’s relatively no change in overall trends from 2014. No change means everyone is using good antibiotic stewardship practices.”
Global Glaucoma Market 2016 – Valuations, Analysis & Forecast – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Glaucoma Market and Competitive Landscape Highlights – 2016” report to their offering. The latest research report provides comprehensive insights into pipeline prod…
Morning Break: Easy Dementia Screen; Real Surgical Robot
(MedPage Today) — Health news and commentary from around the Web, gathered by the MedPage Today staff
Uncategorized
Early response to anti-VEGF therapy for DME may predict 3-year outcome
SEATTLE — Optimal and suboptimal early responses to anti-VEGF therapy tended to predict long-term outcomes in patients treated for diabetic macular edema, according to data presented at the Association for Research in Vision and Ophthalmology meeting.In an interview with Ocular Surgery News, Scott M. Whitcup, MD, discussed results of a post hoc analysis of data from the DRCR.net Protocol I study.